Document ID: chunk:federal_register_of_legislation:F2023L01439:reg:9:p2
Version: federal_register_of_legislation:F2023L01439
Segment Type: reg
Provision Reference: reg 9 (pt 2/5)
Character Range: 10398–13493

duration at the time of the clinical onset of generalised anxiety disorder;
Note: persistent pain is defined in the Schedule 1 – Dictionary.
(13)      being obese at the time of the clinical onset of generalised anxiety disorder;
Note: being obese is defined in the Schedule 1 – Dictionary.
(14)      inability to undertake physical activity greater than 3 METs for a continuous period of at least the 3 months before the clinical onset of generalised anxiety disorder;
Note: MET is defined in the Schedule 1 – Dictionary
(15)      having another medical condition, including an endocrine, cardiovascular, respiratory, metabolic, infectious or neurological disorder, where the signs or symptoms of anxiety are directly related to the pathological process of the medical condition and not solely due to its psychosocial stress effects, at the time of the clinical onset of "anxiety disorder due to another medical condition";
(16)      taking mefloquine within the 24 hours before the clinical onset of substance/medication-induced anxiety disorder, where substance/medication-induced anxiety disorder persists after the discontinuation or tapering of mefloquine therapy;
(17)      using a psychoactive substance from the specified list of psychoactive substances at an intoxicant dose within the 24 hours before the clinical onset of substance/medication-induced anxiety disorder;
Note: intoxicant dose and specified list of psychoactive substances are defined in the Schedule 1 – Dictionary.
(18)      taking a drug that cannot be ceased or substituted in the long term and which is associated in the individual with the development of anxiety symptoms during drug therapy and either:
(a)          the improvement of anxiety symptoms within days or weeks of discontinuing or tapering drug therapy; or
(b)          the redevelopment of anxiety symptoms on rechallenge with the same drug;
where the drug was being taken within the 24 hours before the clinical onset of substance/medication-induced anxiety disorder;
(19)      using a psychoactive chemical or substance at an intoxicant dose, which is associated in the individual with the development of anxiety symptoms, and where the psychoactive chemical or substance was being taken within the 24 hours before the clinical onset of substance/medication-induced anxiety disorder;
Note: intoxicant dose is defined in the Schedule 1 – Dictionary.
(20)      having ceased or reduced therapeutic or illicit drug use or other substance use within the 10 days before the clinical onset of substance/medication-induced anxiety disorder;
(21)      having an alcohol use disorder or a substance use disorder at the time of the clinical onset of substance/medication-induced anxiety disorder;
(22)      having smoked tobacco products in an amount of at least 0.5 pack-years before the clinical onset of substance/medication-induced anxiety disorder, and if smoking has ceased before the clinical onset of substance/medication-induced anxiety disorder, then that onset occurred within 3 months of cessation;
Note: one pack-year is defined in the Schedule